MedPath

Comparing the efficacy and safety of the combination of minoxidil 2.5 mg dutasteride 0.5 mg with minoxidil 2.5 mg and dutasteride 0.5 mg alone in the treatment of androgenic alopecia in me

Phase 2
Recruiting
Conditions
Androgenic Alopecia.
Androgenic alopecia
Registration Number
IRCT20240304061159N1
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
45
Inclusion Criteria

Patients aged 18 to 60 years with male androgenetic alopecia grade 2 to 4 vertex of Norwood-Hamilton classification who have not received any other medical treatment for hair loss in the last 6 months

Exclusion Criteria

Patients who are not diagnosed with androgenic alopecia or are being treated with other drugs, and patients with grade I of androgenic alopecia and patients with severe complications after taking drugs are excluded from the study. Liver and TSH tests (tests in the last 6 months can be it is accepted) it is requested that they will be excluded from the study in case of disorder. Patients with a history of hair transplantation and patients with prostate and breast cancer in the last 5 years will be excluded from the study. patients with a history of diseases related to the right ventricle and neurogenic hypotension And spinal injuries are not included in the study.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.